Background
Methods
Statistics
Results
Patients | 82.8% women |
---|---|
Age (years) | 51.4 ± 13.2 |
Anti-CCP | 80.1% positive |
Rheumatoid factor | 75.2% positive |
Disease duration (years) | 9.9 ± 7.9 |
Number of swollen joints | 6.49 ± 5.5 |
Number of tender joints | 5.98 ± 6.4 |
bDMARDs initiated in the study cohort | Infliximab (n = 19), etanercept (n = 59), adalimumab (n = 8), certolizumab (n = 12), golimumab (n = 8), rituximab (n = 30), tocilizumab (n = 8), and abatacept (n = 5); 8% of the patients were biologic naive |
Prednisolone treated | 50.7% |
Prednisolone dose | 7.8 ± 4.68 mg |
DAS28-CRP score | 4.14 ± 1.32) |
Total number of joints examined, n | 5225 |
Joints with SH and no Doppler at baseline, n (%) | 1191 (23%) |
Joints with SH and Doppler at baseline, n (%) | 1151 (22%) |
Time | Grades | Joints with SH without Doppler activity | Joints with SH with Doppler activity | Adjusted odds ratio | p value | ||||
---|---|---|---|---|---|---|---|---|---|
Number of joints | Frequency of improvement | Number of joints | Frequency of improvement | ||||||
Baseline | With improvement | Baseline | With improvement | ||||||
3 months | All grades | 1172 | 637 | 0.54 | 1122 | 594 | 0.53 | 0.35 | < 0.0001 |
Grade 1 | 863 | 441 | 0.51 | 169 | 58 | 0.35 | |||
Grade 2 | 269 | 164 | 0.61 | 494 | 271 | 0.55 | |||
Grade 3 | 40 | 32 | 0.80 | 459 | 265 | 0.58 | |||
6 months | All grades | 1172 | 657 | 0.56 | 1122 | 669 | 0.60 | 0.39 | 0.0003 |
Grade 1 | 863 | 457 | 0.53 | 169 | 58 | 0.34 | |||
Grade 2 | 269 | 167 | 0.62 | 494 | 312 | 0.63 | |||
Grade 3 | 40 | 33 | 0.82 | 459 | 299 | 0.65 |
Improvement in synovial hypertrophy during treatment
Time | SH grade 0 | SH grade 1 | SH grade 2 | SH grade 3 |
---|---|---|---|---|
Baseline | 53.9% | 19.1% | 14.2% | 9.3% |
3 months | 61.1% | 19% | 11% | 5% |
6 months | 61.6% | 19.1% | 10% | 4.3% |